oday are an early indication that QLT's
drug elution technology has the potential to provide a meaningful
therapeutic benefit. To generate proof of concept data for the Company's
proprietary punctal plug drug delivery system, QLT is currently enrolling
patients in the CORE study, a Phase 2, randomized, double blind trial to
assess the safety and efficacy of its latanoprost punctal plug delivery
system for the treatment of glaucoma and ocular hypertension at three
different doses (low, medium, high). The medium dose of latanoprost in the
CORE Study was used in the trial that is being reported today.
QLT Inc. is a global biopharmaceutical company dedicated to the
discovery, development and commercialization of innovative therapies. Our
research and development efforts are focused on pharmaceutical products in
the fields of ophthalmology and dermatology. In addition, we utilize three
unique technology platforms, photodynamic therapy, Atrigel(R) and punctal
plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and
future product opportunities. For more information, visit our web site at
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.
Atrigel is a registered trademark of QLT USA, Inc.
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-aventis.
QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol
"QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."
Certain statements contained in this press release, which are not
historical facts, are "forward-looking statements," as that term is defined
in the Private Securities Litigation Reform Act of 1995 and constitute
"forward-looking information" within the meaning of applicable Canadian
securities laws. Forward-looking statements include, but are not limited
to: our beliefs rePage: 1 2 3 4 Related biology technology :1
. Neurobiological Technologies Reports Third Quarter Financial Results2
. Bionovo Reports First Quarter 2008 Financial Results3
. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting4
. Cardium Reports on First Quarter 2008 Highlights and Financial Results5
. Novavax Reports First Quarter 2008 Financial Results6
. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance7
. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results8
. Pharmos Corporation Reports 2008 First Quarter Results9
. Halozyme Therapeutics Reports 2008 First Quarter Financial Results10
. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 200811
. Favrille Reports First Quarter 2008 Financial Results